Top Tweets for #CEACAM5
LigaChem Bio plans to begin clinical trials of the world’s first bispecific ADC targeting both CD20 and CD22.
#ADC #Pfizer #LigaChemBiosciences #CD20 #CD22 #AstraZeneca #Enhertu #bispecificADC #CEACAM5 #Besponsa #Sanofi #DaiichiSankyo #ResearchandMarkets
https://t.co/ZINKZhXoYH
📣Call for Reading:
#Communication
A Multimode Microfiber Specklegram Biosensor for Measurement of CEACAM5 through AI Diagnosis
by Yuhui Liu, et al.
https://t.co/xZpz0U8CWH
#multimode #microfiber #specklegram #CEACAM5 #AI
#biosensors #mdpi #openaccess

Don’t miss the program chair, Martin F. Dietrich, MD, PhD, & expert speakers, David Planchard, MD, PhD & Ming Tsao, FRCPC, MD, at our satellite symposium on CEACAM5. Register now: https://t.co/ye6fd43958 #gotoPER #NACLC23 #lcsm @DoctorDietrich @dplanchard

Join us on July 11th at 5:30pmfor a 60-minute educational webinar covering the role #Biomarkers play in #NSCLC including #CEACAM5 with @HatimHusainMD from @UCSDCancer_COE Register at https://t.co/s3LxFTUeaB

Dr. @Joshua_Reuss gives a great talk at #TexasLung23 on antibody drug conjugates including ADCs targeting #Trop2 #HER2 #HER3 #B7H7 #CEACAM5. Important class of agents, each with a unique target and set of toxicities. How will we use these in the future: combinations? 1L?

19b) Findings support #CEACAM5 as a potential therapeutic target and clinical development of #ADCs
🫁 CEACAM5 is preferentially expressed in #NSQ #NSCLC rather than in SQ NSCLC
🫁 #Tusamitamab_ravtansine is the first CEACAM5 emaytansinoid ADC to be evaluated in human subjects

19a) We mentioned Anti-#CEACAM5 therapy above . . . CEACAM5 is a #glycoprotein implicated in a variety of oncogenic activities, and was first recognized as a marker for #coloncancer.

🚨🫁Great #tweetorial by @NarjustFlorezMD & @ShrutiPatelMD on #CEACAM5 🎯 #ADC
A few things to 🤔
➡️#NSQ express more #CEACAM5 than #SQ: ⬆️ #Tusa activity
➡️Role of combos to ⬆️ activity in #SQ
➡️Activity in #CEACAM5 ⬇️ & intmdte
➡️Role of #CEA as a serum marker
#lcsm #OncTwitter
1a) Welcome to our #accredited #tweetorial on The Role of #CEACAM5-Targeted Therapeutics in Patients with CEA-Positive #NSCLC. #LCSM @MedTweetorials
23b)
🫁 ~20% of patients with #NSCLC #adenocarcinoma have an overexpression of #CEACAM5, and CEACAM5 is NOT found in normal lung tissue
🫁 #Tusamitamab_ravtansine is a 🥇in class #CEACAM5-targeted #ADC currently undergoing clinical trials.
23a) To 🎁 up, 🔑points:
🫁 36% of patients with #NSCLC do NOT have a driver mutation that is targetable by an @US_FDA approved drug
🫁 A novel target, carcinoembryonic antigen–related cell adhesion molecule 5 (#CEACAM5) known to us from #coloncancer, may hold promise
22) #CEACAM5 is preferentially expressed in #NSQ_NSCLC rather than in SQ NSCLC. The phase II trial of #tusamitamab_ravtansine showed promising antitumor activity in heavily pretreated advanced NSQ NSCLS with CAECAM5 expression >= 50% of tumor cells. ORR: 20.3%, mDoR: 5.6mo.

20) The big challenge ⚠️ that we have with enrollment, especially in the frontline setting but in all settings as well, is that patients need to have a ➕ #CEACAM5 test to enroll.
18)
🏥Phase 2 #CARMEN_LC05 trial https://t.co/Pwt4qSCPBo
💉Comparing #tusamitamab_ravtansine + #pembro vs pembro alone
🦠metastatic #nonsquamous #NSCLC
🔬 >50% of tumor expresses #CEACAM5 at 2+ intensity
17)
🏥#CARMEN_LC04 trial https://t.co/WFDmfLuzeo
💪🏽Single arm
💉#tusamitamab_ravtansine with #ramucirumab
🦠metastatic #nonsquamous #NSCLC
🔬 >50% of tumor expresses #CEACAM5 at 2+ intensity
🦀disease has progressed after platinum+IO
16)
🏥Phase 3 #CARMEN_LC03 trial https://t.co/Qf8QQJaImb
💉Comparing #tusamitamab ravtansine vs #docetaxel
🦠metastatic nonsquamous #NSCLC
🔬 >50% of tumor expresses #CEACAM5 at 2+ intensity
🦀disease has progressed after prior therapy

15b) Answer C! #Tusamitamab_ravtansine is an antibody-drug conjugate #ADC. It is the 🥇in class #CEACAM5-targeted agent.
See J Clin Oncol. 2020;38[15 suppl]:9505
⚗️this ADC = humanized antibody targeting CEACAM5 🤝cytotoxic maytansinoid derivative DM4
![onc_ce's tweet photo. 15b) Answer C! #Tusamitamab_ravtansine is an antibody-drug conjugate #ADC. It is the 🥇in class #CEACAM5-targeted agent.
See J Clin Oncol. 2020;38[15 suppl]:9505
⚗️this ADC = humanized antibody targeting CEACAM5 🤝cytotoxic maytansinoid derivative DM4 https://t.co/9vvm9ny4OD](https://pbs.twimg.com/media/Fmv9r5ZWIAEc6ZW.jpg)
15a) Which of the following is the compound targeting #CEACAM5? 🧪
A.Trastuzumab deruxtecan
B.Amivantamab
C.Tusamitamab ravtansine
D.Patritumab deruxtecan
Most Popular Users

Elon Musk 
@elonmusk
240.5M followers

Barack Obama 
@barackobama
119.3M followers

Donald J. Trump 
@realdonaldtrump
111.7M followers

Cristiano Ronaldo 
@cristiano
110.4M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
97.6M followers

NASA 
@nasa
92.1M followers

Justin Bieber 
@justinbieber
90.9M followers

KATY PERRY 
@katyperry
87.5M followers

Taylor Swift 
@taylorswift13
81.4M followers

Lady Gaga 
@ladygaga
72.9M followers

Kim Kardashian 
@kimkardashian
69.7M followers

Virat Kohli 
@imvkohli
69.7M followers

YouTube 
@youtube
68.7M followers

Bill Gates 
@billgates
63.8M followers

The Ellen Show
@theellenshow
62.5M followers

Neymar Jr 
@neymarjr
62.4M followers

CNN 
@cnn
61.9M followers

X 
@x
60.8M followers

Selena Gomez 
@selenagomez
60.6M followers


















